临床应用--为力苏-动力相关疾病对症治疗的优良之选.ppt

单击此处编辑母版标题样式,单击此处编辑母版文本样式,第二级,第三级,第四级,第五级,*,*,单击此处编辑母版标题样式,单击此处编辑母版文本样式,第二级,第三级,第四级,第五级,*,*,为力苏,：,动力相关疾病对症治疗的优良之选,Elthon-201202-07,目录,胃肠动力障碍是消化系统疾病的常见原因,为力苏,的作用机制,为力苏,的临床应用,功能性消化不良（,FD,）,卓越的疗效和安全性,定义,消化不良,指持续或反复发作的，包括上腹痛、上腹饱胀、早饱、嗳气、恶心、呕吐等一组上腹部症状;,功能性消化不良(,FD,),指有消化不良的,症状，,经生化、内镜和影像检查排除了器质性疾病的临床症候群。,发病情况,据国外报道，人群中消化不良发病率为,19%41%,；国内报道约占消化病门诊患者的,20%52%,。,柯美云等：,功能性消化不良的治疗,胃动力障碍是功能性消化不良（,FD,）的主要因素,Hiroto M,，,Jiro W,，,Hirokazu F,，,et al.Current understanding of pathogenesis of functional dyspepsia.Journal of Gastroenterology and Hepatology,，,2011,，,26,，,Suppl 3,：,53-60.,目录,胃肠动力障碍是消化系统疾病的常见症状,为力苏,的作用机制,为力苏,的临床应用,功能性消化不良（,FD,）,卓越的疗效和安全性,促动力药治疗,FD,疗效确切,Saad RJ,Chey WD.Review article:Current and emerging therapies for functional dyspepsia.Aliment Pharmacol Ther.,2006,24:475-492.,LDQ,：,Leeds,消化不良问卷,一项前瞻性、多中心、随即对照双盲研究，,554,例,FD,患者随即分为,4,组，分别,接受安慰剂、为力苏,50mg,、,100mg,及,200mg,口服，,3,次,/,日。疗程,8,周。,新英格兰医学杂志文章：,为力苏,显著改善,FD,相关症状,Holtmann G,Talley NJ,Liebregts T,et al.A placebo-controlled trial of itopride in functional dyspepsia.N Engl J Med,2006,，,354(8):832-840.,为力苏,治疗,FD,疗效优于莫沙必利,一项随机双盲对照研究，评估伊托必利与莫沙必利治疗,FD,的有效性和安全性，,患者分别接受伊托必利,50mg,，,tid,或莫沙必利,5mg,，,tid,，疗程,2,周。,Amarapurkar D.N,Rank P.Randomized,double-blind,comparative study to evaluate the efficacy and safety of ganaton,(itopride hydrochloride)and mosapride citrate in the management of functional dyspepsia.J.Indian Med.Assoc.,2004,102(12):735-776,目录,胃肠动力障碍是消化系统疾病的常见症状,为力苏,的作用机制,为力苏,的临床应用,功能性消化不良（,FD,）,卓越的疗效和安全性,为力苏,：卓越的促胃肠动力药,Gupta S,Kapoor V,Gupta BM,et al.Effect Of Itopride hydrochloride on QT interval in adult healthy volunteers.Clinical,Pharmacology.JK-Practitioner 2005,，,12(4):207-210.,Charlotte VN,Jeanne PD,Gerard VH,et al.Domperidone and Ventricular Arrhythmia or Sudden Cardiac Death.Drug Saf,2010,33(11):1003-1014.,为力苏,良好的安全性源自两大因素,与,5HT4,受体无亲和力，,不引起心脏不良反应,不经,CYP450,代谢，,减少药物间相互作用,1,、,Mushiroda T,Douya R,Takahara E,et al.The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride,a gastroprokinetic agent:comparison with cisapride and mosapride citrate.Drug Metab Dispos 28(10):1231-1237.,2,、,Spenard J,Lin J,Shen H,et al.Evaluation of vitro inhibitory effect of itopride on Cytochrome P450.Clinical Pharmacology&Therapeutics,2006:52.,3,、,Gupta S,Kapoor V,Gupta BM,et al.Effect Of Itopride hydrochloride on QT interval in adult healthy volunteers.Clinical,Pharmacology.JK-Practitioner 2005,，,12(4):207-210.,为力苏,上市后大规模临床监测证实,临床应用不良事件发生率低,1,、,Ganaton,Post Marketing Surveillance Study Group.Post marketing surveillance study to evaluate the efficacy and safety of Ganaton,（,Itopride Hydrochloride,）,in the management of functional dyspepsia.JAMA,-India,，,2004,，,3,（,4,）：,1-11.,2,、,Jing S,，,Yao-Zong Y,，,Gerald H.Itopride in the Treatment of Functional Dyspepsia in Chinese Patients.Clin Drug Investig,，,2011,：,1-11.,3,、许大波，柯美云,.,新型促胃肠动力药物伊托必利,.,中国新药杂志，,2002,，,11,（,6,）：,449-451.,GERD,FD,糖尿病胃轻瘫,动力相关疾病对症治疗的优良之选,为力苏,总 结,动力障碍在多种消化系统疾病中普遍存在,为力苏,独特双重机制可全面促进胃肠动力,为力苏,是动力相关疾病对症治疗的优良之选,为力苏,简明处方信息,通用名称：,盐酸伊托必利片,包装与规格：,20片/盒，每片50,mg,用法用量：,50,mg/,次，每日三次,疗程：,可至8周,贮藏和有效期,：,常温（,10-30C),保存，,36,个月,禁忌：,1.,因胃肠动力增强可能加重胃肠道出血、机械性梗阻或穿孔的损害，故此类患 者禁用本品。,2.,已知对伊托必利过敏，或对本品中的任何成份有过敏史的患者禁用本品。,谢谢大家！,